Join us

Become part of a unique team committed to making a difference for cancer patients through innovative therapies

Oncoinvent presents a unique opportunity to join an expanding radiopharma biotech company in clinical development. Our team is fully integrated with production, quality control, quality assurance, and clinical operations established in-house. The lead product candidate, Radspherin®, is produced in our state-of-the-art manufacturing facility in Nydalen (Oslo). Working at Oncoinvent offers a dynamic and flexible environment where you will be given the opportunity to develop yourself professionally.

Are you looking for the energy and team spirit in a start-up? We are eager to keep in touch with potential new colleagues who aspire to join our mission of making a difference, who are dedicated team players committed to our common goals.

If you would like to send us an open application, please send your application and résumé to hr@oncoinvent.com. By sending us your personal information, you consent to processing and storage of your data by Oncoinvent.

About

Management

Board of Directors

Radspherin®

Pipeline

Publications

News

Events

Newsletter subscription

Reports and presentations

The Share

IR Contact

+47 22 18 33 05

Oncoinvent ASA Gullhaugveien 7 0484 Oslo Norway

© Oncoinvent. All rights reserved. Design by Anagram Design AS

Øystein Soug

Chief Executive Officer

soug@oncoinvent.com

Oystein Soug has over 15 years of experience in biotechnology, holding several management positions. Most recently, Mr. Soug was CEO of Arxx Therapeutics, where he led the company to initiate the clinical programme and was responsible for the merger with Dutch pharma company Oxitope Pharma to create Calluna Pharma. Prior to Arxx, he served as CFO and then CEO of Targovax, an Oslo listed biotechnology company, which went public during Mr. Soug’s tenure. Mr. Soug started his career in biotech as CFO of Oslo-listed radiopharmaceutical company Algeta. During this period, the company conducted a successful phase 3 trial, launched its radium-223 based prostate cancer drug Xofigo® and out-licensed the drug. Mr. Soug co-led the sale of the company to Bayer in 2014.  

Mr. Soug holds an MSc in Economics and Financial Markets from Universität St. Gallen in Switzerland in 1997

close

Anders Månsson

Chief Executive Officer

mansson@oncoinvent.com

Anders Månsson is a business executive with over 25 years of experience from management roles in the pharmaceutical industry, focusing on commercialisation and M&A + licensing. Mr. Månsson has held leading roles in the industry both in his native Sweden and in other European countries, and he has worked extensively with the USA and Asia as focus markets in global roles.

Mr. Månsson holds a B.Sc. degree in Business & Economics from Lund’s University in Sweden as well as an MBA from Business School Lausanne in Switzerland. He has a broad-based industrial experience, featuring both large multinational companies such as Meda, Ferring & LEO Pharma, and including leading roles in start-ups and smaller biotech companies. On top of his executive role in Oncoinvent, Mr. Månsson holds two non-executive director positions serving on the board of EQL Pharma AB as well Immetric AB, the latter being an investment company focusing on life science.

close